Meeting
2023 ASCO Annual Meeting
Clinical and financial implications of ADUARA trial on a real-world population.
Authors
Bharathi Muthusamy
Cleveland Clinic, Cleveland, OH
Bharathi Muthusamy , Emily Craig Zabor , Nathan A. Pennell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8526)
DOI
10.1200/JCO.2023.41.16_suppl.8526
Abstract #
8526
Poster Bd #
153
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
First Author: Christopher Lemmon
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2022 ASCO Annual Meeting
Identifying biomarkers associated with disease-free survival in stage I non–small cell lung cancer.
First Author: Christopher W. Seder
Poster
2022 ASCO Annual Meeting
Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.
First Author: Jay M. Lee